Free Newsletter
Sanofi CEO: Think small in Big Pharma
While Sanofi-Aventis CEO Chris Viehbacher (photo) was in Seattle for the Pacific Health Summit--where he touted Sanofi's efforts in emerging markets--a business pub collared him for a Q&A. He talked H1N1 flu, tuberculosis, biotech and targeted meds. Here are some highlights from Xconomy.
- "You're getting into a greater subcategorization of disease. You might say there's not a lot of unmet need in cardiovascular disease. ... [T]here's not unmet need in lowering LDL cholesterol, but there's probably still unmet need in raising HDL. So you have to look much more closely. ... The big one-size-fits-all medicine is a thing of the past."
- The traditional, integrated pharma model is passé, he said. Sure, Big Pharma is still quite good at commercialization of meds, dealing with regulators, etc. Now, drugmakers need to be close to biotechs and academia to "capture some of that innovative genius." He dismissed the break-up-R&D-into-small-units strategy. Biotechs have entirely different cultures and working environments. "Just because you have the same size as a team, that's the same size of a biotech, doesn't mean you within pharma are like a biotech," he said.
- Growing in emerging markets requires different strategies that aren't so reliant on patent protection, he points out. Drugmakers need a business model that allows them to be profitable in those markets, without the blockbuster-patent cycle. In the past, "We started with a medicine and looked for customers," typically the wealthiest customers. "Now, what we're starting to do is say ‘let's start with patients' and say ‘what are their healthcare issues on a market-by-market basis?' Where can we find a business opportunity... It's a much more patient-oriented, and customer-oriented approach than what we've had in the past."
Straight from the horse's mouth. It's a lengthy interview, so check out the full article for details.
- read the piece in Xconomy
Related Articles:
Sanofi chief: Deal denial is 'rock solid'
Lacking details, we read Sanofi's tea leaves
Sanofi CEO eyes small deals, smaller costs
Comments
By H Rutner | Posted 2:19pm | June 19, 2009
I fully concur with Chris on his 3 major points and would like to elaborate some of them. The current big pharma model is truly flawed in its focus on profit driven R&D in a "bean counter" culture seeking to enrich management and Wall Streeters at the expense of low-income seniors and in failing to address patient needs, especially in impoverished underdeveloped nations. There should be a moratorium on new or improved Rx drugs for disease categories already brimming with huge choices of marginally different efficacies. And new entity drug discovery should become the domain of academics and small biotechs, i.e. true innovators unemcumbered by profit pressures from managements pleasing the investment community. Meaning that the current trend among academics focusing on IP protected product research and acting like industrial profiteers must be reversed.
As an R&D scientist who had worked for a then "ethical drug" company, now an 800 lb gorilla, back in the 50's and 60's, I would like to see a return to a business strategy emphasizing patient needs rather than block buster returns. There is also a need both for increased consumer education and pressure on food producers/providers by appropriate government agencies to ensure healthier diets and life styles that would dramatically reduce health care expenses linked to true mal-nutrition, the alleged cause of as much as 50% of patient traffic in drs offices!
H Rutner, Biotech consultant
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: